Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis

Sponsor
Pfizer
Study ID
NCT03387423
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Patients who are started on Tofacitinib treatment according to the drug label

Study Details

This non-interventional study aims to identify key factors that are driving treatment decisions by rheumatologists in the treatment of rheumatoid arthritis (RA) patients starting treatment with Tofacitinib in a real world setting.

Key Dates

Start date
Nov 2, 2017
Status verified
Jul 2024
Primary completion
Jul 17, 2023
Completion
Jul 17, 2023

Study Design

Enrollment
1,459 participants (actual)

Primary Outcome Measure

Number of Participants With Treatment Escalations [ Time Frame: From date of first prescription of tofacitinib up to 24 Months ]

Related Studies